| |
| |
|
| Insider
Information: |
Edick Paul R |
| Relationship: |
Chief Executive Office... |
| City: |
Aimes |
| State: |
IA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
278,495 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$603,601 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
278,495 |
|
|
| Total
Value |
$603,601 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
0.0
|
| Percentage
Gain/Loss : |
 22.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Durata Therapeutics, Inc. |
DRTX |
Chief Executive Office... |
2012-08-14 |
24,636 |
2014-11-17 |
0 |
Premium* |
|
|
Lumos Pharma Inc |
LUMO |
Director |
2015-04-30 |
7,906 |
2014-01-02 |
0 |
Premium* |
|
|
PDL Biopharma Inc |
PDLI |
Director |
2018-06-08 |
214,563 |
2015-09-08 |
0 |
Premium* |
|
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
Director |
2018-02-13 |
0 |
2016-08-01 |
0 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
Director |
2019-05-24 |
31,390 |
2018-05-30 |
0 |
Premium* |
|
|
Xeris Pharmaceuticals Inc |
XERS |
Chief Executive Office... |
2021-10-05 |
0 |
2021-10-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XERS |
Xeris Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(608,064) |
0 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2021-10-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,430) |
0 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
225,000 |
636,134 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2020-12-09 |
4 |
B |
$4.06 |
$40,551 |
D/D |
10,000 |
411,134 |
2.81 |
% |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2020-05-08 |
4 |
B |
$3.00 |
$99,000 |
D/D |
33,000 |
401,134 |
2.81 |
% |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2020-02-14 |
4 |
B |
$4.15 |
$83,000 |
D/D |
20,000 |
183,134 |
2.81 |
% |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2020-01-31 |
4 |
D |
$6.37 |
$62,432 |
D/D |
(9,801) |
163,134 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
368,134 |
0 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
Director |
– • – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
31,390 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2019-03-11 |
4 |
B |
$9.12 |
$273,585 |
D/D |
30,000 |
155,000 |
2.81 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
Director |
– • – |
2018-08-23 |
4 |
B |
$10.44 |
$5,219 |
D/D |
500 |
25,236 |
2.39 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
See Remarks |
• • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
13,430 |
13,430 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2018-06-08 |
4 |
A |
$2.76 |
$150,000 |
D/D |
54,348 |
214,563 |
0 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
Director |
– • – |
2018-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,554 |
24,736 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2018-02-13 |
4 |
D |
$18.00 |
$268,740 |
D/D |
(14,930) |
0 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2017-06-09 |
4 |
A |
$2.47 |
$150,001 |
D/D |
60,729 |
160,215 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
14,930 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2017-06-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
5,130 |
19,830 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2016-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,700 |
14,700 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2016-06-02 |
4 |
A |
$3.52 |
$250,001 |
D/D |
71,023 |
99,486 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2015-09-08 |
4 |
A |
$5.27 |
$150,000 |
D/D |
28,463 |
28,463 |
0 |
- |
|
| LUMO |
Lumos Pharma Inc |
Director |
– • – |
2015-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,962 |
7,906 |
0 |
- |
|
| DRTX |
Durata Therapeutics, Inc. |
Chief Executive Officer |
• • – |
2014-11-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(46,136) |
0 |
0 |
- |
|
| DRTX |
Durata Therapeutics, Inc. |
Chief Executive Officer |
• • – |
2014-06-12 |
4 |
B |
$15.23 |
$45,690 |
I/I |
3,000 |
45,636 |
2.66 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
